Help patients within the growing space of substance use disorders and mental health

Q2 2020 - Building for future growth

JULY 16 2020 - In Q2, the focus was to prepare for an accelerated launch of the digital offering and the pipeline advanced as OX125 showed strong study results. According to expectations, ZUBSOLV® volume declined YoY, due to the changed position at United Health Group. In parallel, ZUBSOLV® continued to show strong profit and cash contribution, which partially compensated for the increased investments in DTx and RnD.

Q2 Interim Report Presentation

JULY 16 2020 - Listen to the recorded Q2 2020 Interim Report Presentation. Nikolaj Sørensen CEO and Joseph DeFeo CFO presented the report and answered questions about the latest development and the way going forward.

Launch of deprexis® and vorvida® initiated in the US

JULY 2 2020 - Today the company announces the US launch of its scientifically proven digital therapies deprexis® and vorvida® has been initiated. The decision to accelerate the launch of the digital offering, also incl. OXD01, is based on the patient need for access to low-risk clinically-validated digital health devices during the ongoing COVID-19 pandemic and the recent FDA “Enforcement Policy” providing a fast pathway to market. The accelerated launch will increase investments and OPEX FY 2020 expects to be in the range of SEK 780-800 m.

Positive results from OX125 human PK study

JUNE 30, 2020 - Preliminary results for OX125 indicate extensive and rapid absorption across all formulations as well as good tolerability, supporting the viability of OX125 as a rescue medication for opioid overdose. OX125 could be an important addition to OX124 and the results underline the applicability of Orexo’s novel intranasal drug delivery platform.